If efficiently and safely scaled up in DMD patients, this technique could lead to one of the first successful genome editing-based treatments for this fatal disease, researchers said.
DMD, the most common and severe form of muscular dystrophy among boys, is characterized by progressive muscle degeneration and weakness. It is caused by mutations in the X-linked DMD gene that encodes the protein dystrophin. The disease affects one in 3,500 to 5,000 boys, according to the Centers for Disease Control and Prevention and other estimates, and often leads to premature death by the early 30s.
Although the genetic cause of DMD has been known for nearly 30 years, no effective treatments exist. The disease breaks down muscle fibers and replaces them with fibrous or fatty tissue, causing the muscle to gradually weaken. This condition often results in heart muscle disease, or cardiomyopathy, the leading cause of death in these patients.
In the study published today in Science, UTSW researchers used a gene-editing approach to permanently correct the DMD mutation that causes the disease in young mice.
“This is different from other therapeutic approaches, because it eliminates the cause of the disease,” said senior author Dr. Eric Olson, Chairman of Molecular Biology, and Co-Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center at UT Southwestern.
In 2014, Dr. Olson’s team first used this technique – called CRISPR/Cas9-mediated genome editing – to correct the mutation in the germ line of mice and prevent muscular dystrophy. This paved the way for novel genome editing-based therapeutics in DMD. It also raised several challenges for clinical applications of gene editing. Since germ line editing is not feasible in humans, strategies would need to be developed to deliver gene-editing components to postnatal tissues.
To test this out, researchers delivered gene-editing components to the mice via adeno-associated virus 9 (AAV9). DMD mice treated with this technique produced dystrophin protein and progressively showed improved structure and function of skeletal muscle and heart.
“AAV9 can efficiently infect humans in a tissue-specific manner, but it does not cause human disease or toxicity. It’s a molecular missile for gene therapy,” said Dr. Leonela Amoasii, a postdoctoral researcher in the Olson lab and co-lead author of the study with Dr. Chengzu Long, Instructor of Molecular Biology.
“The CRISPR/Cas9 system is an adaptive immune system of single-celled organisms against invading virus. Ironically, this system was hijacked, we packaged it into a nonpathogenic virus, and corrected a genetic mutation in an animal model,” added Dr. Long.
The CRISPR genome-editing technology, which was developed by a researcher at University of California at Berkeley, was picked as the “Breakthrough of the Year” scientific development by Science.
“This study represents a very important translational application of genome editing of DMD mutations in young mice. It’s a solid step toward a practical cure for DMD,” said Dr. Rhonda Bassel-Duby, Professor of Molecular Biology and Co-Principal Investigator of a genomic editing project with Dr. Olson at the Wellstone Center.
“Importantly, in principle, the same strategy can be applied to numerous types of mutations within the human DMD patients,” added Dr. Olson, who also serves as Director of the Hamon Center for Regenerative Science and Medicine, and holds the Annie and Willie Nelson Professorship in Stem Cell Research, the Pogue Distinguished Chair in Research on Cardiac Birth Defects, and the Robert A. Welch Distinguished Chair in Science.
Now, the research team is working to apply this gene-editing technique to cells from DMD patients and in larger preclinical animal models.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Sarepta Investors Buckle Up for Pfizer’s DMD Gene Therapy Updateon May 12, 2020 at 6:05 am
A fresh look at how a handful of patients are faring on Pfizer Inc.’s gene therapy for Duchenne muscular dystrophy will be key for investors in competitor Sarepta Therapeutics Inc.Underwhelming effect ...
- Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophyon May 12, 2020 at 5:29 am
Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy ...
- Dyne Therapeutics Demonstrates FORCE™ Platform’s Potential to Deliver Potent Exon-Skipping Molecules Directly to Muscle to Treat Duchenne Muscular Dystrophyon May 12, 2020 at 4:49 am
Dyne Therapeutics presents data at ASGCT demonstrating improvement in muscle function in a preclinical model of Duchenne muscular dystrophy (DMD).
- PMR : Duchenne Muscular Dystrophy Treatment Market to Record a Robust Growth Rate of CAGR 48.3% During 2026on May 12, 2020 at 12:42 am
As per the report by Persistence Market Research (PMR), the global duchenne muscular dystrophy market is expected to experience strong growth. The market is also estimated to expand at a CAGR of 48.3% ...
- 2020-2026 Duchenne Muscular Dystrophy Therapeutics Market Size, Growth, Production, Types, Applications, Growing Rapidly with Recent Trendson May 11, 2020 at 10:50 pm
Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Duchenne Muscular Dystrophy Therapeutics Market” report provides valuable information regarding new products in ...
- Towards stem cell therapies for skeletal muscle repairon May 11, 2020 at 2:11 am
Skeletal muscle is an ideal target for cell therapy. The use of its potent stem cell population in the form of autologous intramuscular transplantation represents a tantalizing strategy to slow the ...
- Duchenne Muscular Dystrophy Epidemiology: Analysis, and Forecast - 3-year historical and 11-year Forecast Analysison May 8, 2020 at 9:24 pm
As per DelveInsight, the total prevalent population of Duchenne Muscular Dystrophy (DMD) in the seven major markets was found to be 31,386 in 2017 and the total diagnosed prevalent population of ...
- Duchenne Muscular Dystrophy Pipeline Insights: Upcoming therapies that shall drive the market aheadon May 8, 2020 at 4:14 pm
The goal of Duchenne Muscular Dystrophy (DMD) treatment is to control the symptoms of DMD and related complications caused by severe progressive muscle weakness and loss in order ...
- Pfizer to review Duchenne gene therapy data May 15on May 8, 2020 at 8:36 am
Pfizer (PFE +0.5%) will host a conference call on Friday, May 15, at 10:00 am ET to review its Duchenne muscular dystrophy (DMD) data presentation at the American Society of Gene and Cell Ther ...
- No respite for Solid Bio's troubled Duchenne program as FDA keeps it on holdon May 8, 2020 at 7:40 am
Solid Biosciences started 2020 by laying off one-third of its staff and “curtailing” most of its R&D to keep its Duchenne muscular dystrophy treatment afloat. Four months later, those efforts have yet ...
via Bing News